|
Name |
Trivirensol A
|
Molecular Formula | C45H62O16 | |
IUPAC Name* |
(5aS,6R,9S,9aS)-9-[[(E)-3-[(1S,2S,3S,6R)-2-carboxy-3-hydroxy-3-[[(E)-2-(hydroxymethyl)-3-[(4S,5R)-3-oxo-5-propan-2-yl-4,5,6,7-tetrahydro-1H-2-benzofuran-4-yl]prop-2-enoyl]oxymethyl]-6-propan-2-ylcyclohexyl]-2-(hydroxymethyl)prop-2-enoyl]oxymethyl]-9-hydroxy-1-oxo-6-propan-2-yl-3,5a,6,7,8,9a-hexahydro-2-benzoxepine-4-carboxylic acid
|
|
SMILES |
CC(C)[C@H]1CCC2=C([C@@H]1/C=C(\CO)/C(=O)OC[C@@]3(CC[C@@H]([C@H]([C@@H]3C(=O)O)/C=C(\CO)/C(=O)OC[C@@]4(CC[C@@H]([C@@H]5[C@@H]4C(=O)OCC(=C5)C(=O)O)C(C)C)O)C(C)C)O)C(=O)OC2
|
|
InChI |
InChI=1S/C45H62O16/c1-22(2)29-8-7-25-18-58-42(54)35(25)32(29)13-26(16-46)40(52)60-20-44(56)11-9-30(23(3)4)33(36(44)39(50)51)14-27(17-47)41(53)61-21-45(57)12-10-31(24(5)6)34-15-28(38(48)49)19-59-43(55)37(34)45/h13-15,22-24,29-34,36-37,46-47,56-57H,7-12,16-21H2,1-6H3,(H,48,49)(H,50,51)/b26-13+,27-14+/t29-,30-,31-,32-,33-,34-,36-,37-,44-,45-/m1/s1
|
|
InChIKey |
BSUKTQJHXQIJRW-UEMMTAFQSA-N
|
|
Synonyms |
CHEMBL4436622; Trivirensol A; BDBM50509323
|
|
CAS | NA | |
PubChem CID | 145721277 | |
ChEMBL ID | CHEMBL4436622 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 859.0 | ALogp: | 3.2 |
HBD: | 6 | HBA: | 16 |
Rotatable Bonds: | 17 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 261.0 | Aromatic Rings: | 5 |
Heavy Atoms: | 61 | QED Weighted: | 0.077 |
Caco-2 Permeability: | -6.185 | MDCK Permeability: | 0.00003650 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.993 |
Human Intestinal Absorption (HIA): | 0.899 | 20% Bioavailability (F20%): | 0.993 |
30% Bioavailability (F30%): | 0.998 |
Blood-Brain-Barrier Penetration (BBB): | 0.082 | Plasma Protein Binding (PPB): | 86.21% |
Volume Distribution (VD): | 0.446 | Fu: | 2.09% |
CYP1A2-inhibitor: | 0.005 | CYP1A2-substrate: | 0.042 |
CYP2C19-inhibitor: | 0.008 | CYP2C19-substrate: | 0.05 |
CYP2C9-inhibitor: | 0.095 | CYP2C9-substrate: | 0.043 |
CYP2D6-inhibitor: | 0.003 | CYP2D6-substrate: | 0.034 |
CYP3A4-inhibitor: | 0.102 | CYP3A4-substrate: | 0.18 |
Clearance (CL): | 4.243 | Half-life (T1/2): | 0.296 |
hERG Blockers: | 0.026 | Human Hepatotoxicity (H-HT): | 0.192 |
Drug-inuced Liver Injury (DILI): | 0.959 | AMES Toxicity: | 0.01 |
Rat Oral Acute Toxicity: | 0.714 | Maximum Recommended Daily Dose: | 0.971 |
Skin Sensitization: | 0.251 | Carcinogencity: | 0.31 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.023 |
Respiratory Toxicity: | 0.834 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004012 | 0.732 | D0FW2A | 0.215 | ||||
ENC003999 | 0.514 | D06OMK | 0.199 | ||||
ENC004063 | 0.487 | D0D0SH | 0.198 | ||||
ENC004002 | 0.476 | D0ES1Q | 0.198 | ||||
ENC003589 | 0.308 | D0AT8C | 0.197 | ||||
ENC002578 | 0.304 | D0K7HU | 0.197 | ||||
ENC004919 | 0.301 | D0X4RS | 0.196 | ||||
ENC004003 | 0.283 | D05RXI | 0.194 | ||||
ENC005682 | 0.269 | D0S0NK | 0.194 | ||||
ENC004921 | 0.256 | D0M2QH | 0.192 |